Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody targets the p19 subunit of interleukin 23. Mirikizumab can be used for the research of ulcerative colitis.
References:
[1]. Jefremow A, et al. Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective. Immunotargets Ther. 2020 Nov 26;9:289-297.
















